Azacitidine and the beginnings of therapeutic epigenetic modulation Journal Article


Authors: O'dwyer, K.; Maslak, P.
Article Title: Azacitidine and the beginnings of therapeutic epigenetic modulation
Abstract: Background: Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics. Objective: What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)? Methods: We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication. Conclusion: The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients. © 2008 Informa UK Ltd.
Keywords: treatment outcome; clinical trial; constipation; fatigue; neutropenia; review; area under the curve; diarrhea; drug penetration; side effect; clinical trials as topic; bolus injection; low drug dose; enzyme inhibition; liver toxicity; gene expression; anemia; bone marrow suppression; antimetabolites, antineoplastic; protein metabolism; leukopenia; thrombocytopenia; continuous infusion; drug structure; drug fever; gastrointestinal toxicity; hypokalemia; myelodysplastic syndrome; rigor; drug mechanism; tissue distribution; epigenetics; epigenesis, genetic; single drug dose; nausea and vomiting; weakness; drug bioavailability; drug labeling; maximum plasma concentration; drug metabolism; blood cell count; drug blood level; drug cytotoxicity; drug half life; dna methyltransferase; drug transport; injection site erythema; drug excretion; azacitidine; myelodysplastic syndromes; drug urine level; ecchymosis; drug degradation; drug elimination; petechia; hemoglobin f; cancer epigenetics; drug activation; drug feces level
Journal Title: Expert Opinion on Pharmacotherapy
Volume: 9
Issue: 11
ISSN: 1465-6566
Publisher: Informa Healthcare  
Date Published: 2008-08-01
Start Page: 1981
End Page: 1986
Language: English
DOI: 10.1517/14656566.9.11.1981
PUBMED: 18627335
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 5" - "Export Date: 17 November 2011" - "CODEN: EOPHF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Peter Maslak
    197 Maslak